• 1
    Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab 2008; 93(Suppl): S9S30.
  • 2
    Greenfield V, Cheung O, Sanyal AJ. Recent advances in nonalcholic fatty liver disease. Curr Opin Gastroenterol 2008; 24: 320327.
  • 3
    Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008; 51: 19471953.
  • 4
    Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 17961808.
  • 5
    Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004; 24: 320.
  • 6
    Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003; 144: 51595165.
  • 7
    Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 2008; 7: 9596.
  • 8
    Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) 2008; 115: 141150.
  • 9
    Holland WL, Summers SA. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev 2008; 29: 381402.
  • 10
    Inokuchi J. Insulin resistance as a membrane microdomain disorder. Yakugaku Zasshi 2007; 127: 579586.
  • 11
    Kabayama K, Sato T, Kitamura F, Uemura S, Kang BW, Igarashi Y, et al. TNFalpha-induced insulin resistance in adipocytes as a membrane microdomain disorder: involvement of ganglioside GM3. Glycobiology 2005; 15: 2129.
  • 12
    Yamashita T, Hashiramoto A, Haluzik M, Mizukami H, Beck S, Norton A, et al. Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc Natl Acad Sci U S A 2003; 100: 34453449.
  • 13
    Kabayama K, Sato T, Saito K, Loberto N, Prinetti A, Sonnino S, et al. Dissociation of the insulin receptor and caveolin-1 complex by ganglioside GM3 in the state of insulin resistance. Proc Natl Acad Sci U S A 2007; 104: 1367813683.
  • 14
    Bonzon-Kulichenko E, Schwudke D, Gallardo N, Molto E, Fernandez-Agullo T, Shevchenko A, et al. Central leptin regulates total ceramide content and sterol regulatory element binding protein-1C proteolytic maturation in rat white adipose tissue. Endocrinology 2009; 150: 169178.
  • 15
    Aerts JM, Ottenhoff R, Powlson AS, Grefhorst A, van Eijk M, Dubbelhuis PF, et al. Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes 2007; 56: 13411349.
  • 16
    Zhao H, Przybylska M, Wu IH, Zhang J, Siegel C, Komarnitsky S, et al. Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes 2007; 56: 12101218.
  • 17
    van Eijk M, Aten J, Bijl N, Ottenhoff R, van Roomen CP, Dubbelhuis PF, et al. Reducing glycosphingolipid content in adipose tissue of obese mice restores insulin sensitivity, adipogenesis and reduces inflammation. PLoS One 2009; 4: e4723.
  • 18
    Overkleeft HS, Renkema GH, Neele J, Vianello P, Hung IO, Strijland A, et al. Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase. J Biol Chem 1998; 273: 2652226527.
  • 19
    Ghauharali-van d, V, Langeveld M, Poppema A, Kuiper S, Hollak CE, Aerts JM, et al. Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease. Clin Chim Acta 2008; 389: 109113.
  • 20
    Dokun AO, Chu DT, Yang L, Bendelac AS, Yokoyama WM. Analysis of in situ NK cell responses during viral infection. J Immunol 2001; 167: 52865293.
  • 21
    Fan JB, Gunderson KL, Bibikova M, Yeakley JM, Chen J, Wickham GE, et al. Illumina universal bead arrays. Methods Enzymol 2006; 410: 5773.
  • 22
    Nikolsky Y, Nikolskaya T, Bugrim A. Biological networks and analysis of experimental data in drug discovery. Drug Discov Today 2005; 10: 653662.
  • 23
    Garcia-Ruiz I, Rodriguez-Juan C, az-Sanjuan T, del HP, Colina F, Munoz-Yague T, et al. Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice. HEPATOLOGY 2006; 44: 581591.
  • 24
    Ferrante AW Jr, Thearle M, Liao T, Leibel RL. Effects of leptin deficiency and short-term repletion on hepatic gene expression in genetically obese mice. Diabetes 2001; 50: 22682278.
  • 25
    Liang CP, Tall AR. Transcriptional profiling reveals global defects in energy metabolism, lipoprotein, and bile acid synthesis and transport with reversal by leptin treatment in ob/ob mouse liver. J Biol Chem 2001; 276: 4906649076.
  • 26
    Bijl N, van Roomen CP, Triantis V, Sokolovic M, Ottenhoff R, Scheij S, et al. Reduction of glycosphingolipid biosynthesis stimulates biliary lipid secretion in mice. HEPATOLOGY 2009; 49: 637645.
  • 27
    Lieber CS, Weiss DG, Paronetto F. Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease. Alcohol Clin Exp Res 2008; 32: 10311039.
  • 28
    McCrudden R, Iredale JP. Liver fibrosis, the hepatic stellate cell and tissue inhibitors of metalloproteinases. Histol Histopathol 2000; 15: 11591168.
  • 29
    Ikejima K, Okumura K, Lang T, Honda H, Abe W, Yamashina S, et al. The role of leptin in progression of non-alcoholic fatty liver disease. Hepatol Res 2005; 33: 151154.
  • 30
    Wiegman CH, Bandsma RH, Ouwens M, van der Sluijs FH, Havinga R, Boer T, et al. Hepatic VLDL production in ob/ob mice is not stimulated by massive de novo lipogenesis but is less sensitive to the suppressive effects of insulin. Diabetes 2003; 52: 10811089.
  • 31
    Ikejima K, Okumura K, Kon K, Takei Y, Sato N. Role of adipocytokines in hepatic fibrogenesis. J Gastroenterol Hepatol 2007; 22(Suppl 1): S87S92.
  • 32
    Kitade M, Yoshiji H, Kojima H, Ikenaka Y, Noguchi R, Kaji K, et al. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. HEPATOLOGY 2006; 44: 983991.
  • 33
    Kremer M, Hines IN. Natural killer T cells and non-alcoholic fatty liver disease: fat chews on the immune system. World J Gastroenterol 2008; 14: 487488.
  • 34
    Wang ZV, Scherer PE. Adiponectin, cardiovascular function, and hypertension. Hypertension 2008; 51: 814.
  • 35
    Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? HEPATOLOGY 2004; 40: 4654.
  • 36
    Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91100.
  • 37
    Langeveld M, Aerts JM. Glycosphingolipids and insulin resistance. Prog Lipid Res 2009; 48: 196205.
  • 38
    Zigmond E, Zangen SW, Pappo O, Sklair-Levy M, Lalazar G, Zolotaryova L, et al. Beta-glycosphingolipids improve glucose intolerance and hepatic steatosis of the Cohen diabetic rat. Am J Physiol Endocrinol Metab 2009; 296: E72E78.